Skip to content
BiologicalX

Comparison

NMN vs Thymosin Alpha-1

Side-by-side of NMN and Thymosin Alpha-1. Every row below is pulled from the compound schema and will update as our data grows. For deeper reads, follow through to each compound page.

Effects at a glance

NMN

  • Plasma NAD+ rises 30-90% at 250-1000 mg/day across human PK studies
  • Tissue NAD+ rise is inconsistent across human trials (Yoshino 2021, Igarashi 2022)
  • No human trials measure hard endpoints (mortality, CV events, cancer); evidence is biomarker-only
  • Most trials cluster at 250-500 mg/day; dose-response above 250 mg/day is poorly characterized
  • FDA position contested; widely sold as supplement but with regulatory uncertainty
  • Marketing claims for fertility and longevity outrun the human trial evidence substantially

Thymosin Alpha-1

  • 28-amino-acid synthetic peptide identical to thymic-derived immunomodulator
  • Approved in over 35 countries as Zadaxin for hepatitis B, hepatitis C adjunct, and immune support
  • Not FDA approved in US; compounded by 503A/503B pharmacies for off-label immune support
  • Modulates T-cell maturation, NK activity, and Th1 polarization in immunocompromised states
  • Standard label dose: 1.6 mg subcutaneously twice weekly
  • Cleanest safety profile in the peptide class with hundreds of regulated trials behind it

Side-by-side

Attribute NMN Thymosin Alpha-1
Category supplement peptide
Also known as nicotinamide mononucleotide, beta-NMN Talpha1, Ta1, Zadaxin, Thymalfasin
Half-life (hr) 4 2
Typical dose (mg) 250 1.6
Dosing frequency 1x daily, often morning 2x weekly
Routes oral, sublingual subcutaneous, intramuscular
Onset (hr) 1 24
Peak (hr) 3 168
Molecular weight 334.22 3108.32
Molecular formula C11H15N2O8P C129H215N33O55
Mechanism Direct precursor in the NAD+ salvage pathway; converted to NAD+ by NMNAT enzymes in essentially every tissue. Raised NAD+ supports sirtuin and PARP enzyme activity. Synthetic peptide modulator of innate and adaptive immunity. Promotes T-cell maturation and CD4/CD8 production, modulates Th1/Th2 balance, stimulates NK cell activity, and modulates TLR2/TLR9 signaling in dendritic cells.
Legal status Contested in US (FDA position 2022); widely sold as supplement; broadly available in EU, UK, Asia Approved in 35+ countries as Zadaxin (hepatitis B, hepatitis C adjunct, immune support); not FDA approved in US; compounded by 503A/503B pharmacies for off-label use; not on WADA Prohibited List
WADA status allowed unknown
DEA / Rx Not scheduled Rx only via international approval or US compounding (no controlled-substance schedule)
Pregnancy Insufficient data; precautionary avoidance Not recommended; insufficient data
CAS 1094-61-7 62304-98-7
PubChem CID 14180 16130571
Wikidata Q418972 Q913854

Safety profile

NMN

Common side effects

  • mild GI upset (rare)
  • occasional headache
  • flushing (rare)

Contraindications

  • pregnancy and lactation (precautionary, no data)
  • active cancer (theoretical concern, not evidence-based)

Interactions

  • metformin: no clinically significant interaction documented; both modulate metabolism through different mechanisms(minor)
  • chemotherapy agents: theoretical concern about supporting cancer cell proliferation; coordinate with oncology team(moderate)
  • CD38 inhibitors: would amplify NMN-induced NAD+ rise; not clinically relevant for most users(minor)

Thymosin Alpha-1

Common side effects

  • mild injection-site irritation (rare)
  • transient mild fatigue (rare)
  • occasional headache (rare)

Contraindications

  • pregnancy
  • lactation
  • active organ transplant rejection therapy
  • systemic immunosuppression for autoimmune disease (relative)
  • severe active autoimmune disease (caution)

Interactions

  • interferon-alpha: additive immune effect; used clinically in approved combination protocols(minor)
  • calcineurin inhibitors (cyclosporine, tacrolimus): theoretical destabilization of immunosuppression; avoid(major)
  • antimetabolites (azathioprine, mycophenolate): theoretical destabilization of immunosuppression; avoid(major)
  • vaccine administration: may augment vaccine response in elderly or immunocompromised; coordinate with clinician(minor)

Which Should You Take?

NMN comes out ahead for most readers on the criteria we weight: 3 catalogued goals, Contested in US (FDA position 2022); widely sold as supplement; broadly available in EU, UK, Asia, oral dosing, with a Tier-A outcome catalogued. Thymosin Alpha-1 is the right call when one of the conditionals below applies.

  • If your priority is healthspan extension, pick NMN.
  • If your priority is energy and stamina, pick NMN.
  • If your priority is immune support, pick Thymosin Alpha-1.
  • If your priority is post-training recovery, pick Thymosin Alpha-1.

Edge case: If you cannot self-administer injections, NMN is the only oral option in this pair.

Default choice: NMN. Wider use case, a Tier-A evidence outcome catalogued, and broader goal coverage. Reach for Thymosin Alpha-1 only if your priority sits squarely in the goals it owns above.

This verdict is generated from each compound's schema (goals, legal status, evidence outcomes, dosing route). It updates automatically as our compound data evolves; the deeper read sits on each individual compound page.

Common questions

What is the difference between NMN and Thymosin Alpha-1?

NMN and Thymosin Alpha-1 differ in category (supplement vs peptide), mechanism, and typical dosing. See the side-by-side table for full details.

Which has a longer half-life, NMN or Thymosin Alpha-1?

NMN half-life is 4 hours; Thymosin Alpha-1 half-life is 2 hours.

Can you stack NMN with Thymosin Alpha-1?

Stack compatibility depends on mechanism overlap, legal status, and individual response. Check each compound page for specific interactions and contraindications before combining.

Go deeper